Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
|
|
- Stephanie Simon
- 6 years ago
- Views:
Transcription
1 Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including sponsor and supporter, disclosures, and instructions for claiming credit) are available by visiting: Released: 02/08/2016 Valid until: 02/08/2017 Time needed to complete: 15 minutes ReachMD info@reachmd.com (866) Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE Welcome to CME on ReachMD. This segment, Individualizing VTE Treatment and Prevention of Recurrence: The Place for Novel Oral Anticoagulants in VTE, is jointly provided by Global Education Group and Diversified Health Communications and supported by an educational grant from Boehringer Ingelheim. Your faculty is Dr. Alok Khorana, who is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He is also the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services and Strategy of the Taussig Cancer Institute and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio ReachMD Page 1 of 9
2 Prior to beginning the activity, please be sure to review Dr. Khorana s financial disclosures. Please also review the learning objectives for this activity. Here is your host, Dr. Jennifer Caudle. Venous thromboembolism, or VTE, is an umbrella term for deep vein thrombosis and pulmonary embolism. It is estimated that VTE affects up to 600,000 people each year in the United States. It s associated with significant morbidity and mortality. Approximately 33% of people with VTE will have a recurrence within 10 years, with the risk being greatest in the first 2 years. Also, it is estimated that up to a hundred thousand people die as a result of VTE each year. Today we are addressing the role of novel oral anticoagulants in VTE treatment and prevention of recurrence. Dr. Khorana, welcome to our program. Thank you so much for having me. Dr. Khorana, what are some currently available treatments for VTE and prevention of recurrence? Well, the great news is we have a lot of different options. Warfarin which has been around for a number of decades remains the most widely prescribed oral anticoagulant. We also have heparin which includes unfractionated heparin and lower-molecular-weight heparin which have been replacing unfractionated heparin, fondaparinux which is a factor Xa inhibitor, and in the past few years we ve 2017 ReachMD Page 2 of 9
3 seen the advent of novel oral anticoagulants including dabigatran which is a direct thrombin inhibitor and rivaroxaban, apixaban, and edoxaban which are factor Xa inhibitors. What do the current clinical guidelines recommend for the acute treatment of VTE? In patients starting off with a new diagnosis of either deep vein thrombosis or pulmonary embolism, initial treatment is recommended with parenteral anticoagulation, that s either low-molecular-weight heparin, unfractionated heparin, or fondaparinux. It s important that if you re going to transition the patient to an oral anticoagulant such as warfarin, that warfarin therapy be started as soon as possible in the course of treatment, and patients remain on parenteral therapy for at least 5 days, until the INR is 2 or higher for at least 24 hours. Great. Can you discuss the choice of anticoagulant regimen for long-term therapy? For patients with a DVT or PE and no cancer, the guidelines recommend low-molecular-weight heparin over dabigatran or rivaroxaban for long-term therapy. For patients with DVT and cancer, lowmolecular-weight heparin monotherapy is recommended, and if you re not going to use low-molecularweight heparin therapy, for whatever reason, then Coumadin, or a vitamin K antagonist is preferred over dabigatran or rivaroxaban for long-term treatment according to these slightly older guidelines. So, the newer anticoagulants have just become available and the challenge is that some of the evidence-based guidelines, such as the Chest guidelines, although they were released in 2012 they were prepared in The newer agents were just starting to come on market. The guidelines do mention that rivaroxaban and dabigatran are certainly more convenient for patients, but at that time, given lack ofexperience with the agents outside of clinical trials, they gave a weaker recommendation, in favor of warfarin and low-molecular-weight heparin. In more recent prescription data analysis, it s 2017 ReachMD Page 3 of 9
4 pretty clear that the new direct oral anticoagulants certainly are being widely used in the market as well as initial treatment of VTE. What do the guidelines recommend for prevention of VTE in orthopedic patients? In orthopedic patients, it is primarily patients undergoing either total hip or total knee arthroplasty; at least one of the following drugs are recommended for 10 to 14 days for prophylaxis. It can be lowmolecular-weight heparin, fondaparinux, apixaban, dabigatran, unfractionated heparin, Coumadin, or aspirin. Rivaroxaban and apixaban do also have approval for prophylaxis in this setting as well. For patients undergoing major orthopedic surgery who refuse injection, for comfort reasons or for copayment issues, the guidelines recommend apixaban or dabigatran rather than other forms of prophylaxis. Dr. Khorana, what is the role of new oral anticoagulant agents in the prevention and management of VTE? Those have also been in practice for a while now; the use of warfarin is very challenging because it involves rigorous monitoring, there are issues related to bridging at the time of interruptions or if there are procedural issues, and there s a big problem with drug-drug interactions. I m an oncologist and interactions with chemotherapy is sort of a big issue and there s a lot of inter-patient variability. And there are dietary restrictions as well that are not always followed by patients. And so, although highly effective, warfarin has a lot of challenges. The new oral agents definitely have advantages over warfarin in that their effect is more predictable, it doesn t require monitoring, and there s not a lot of drug-diet interactions and certainly fewer drug-drug interactions. So, in general, the novel oral agents are much more patient-friendly and much more convenient to use. It should be noted that none of the 2017 ReachMD Page 4 of 9
5 newer agents are appropriate for patients who have a heart valve replacement, so the indications are either treatment of VTE or non-valvular heart disease, and so in that setting you would recommend continuing the use of warfarin. What about for patients with cancer-associated VTE? So, VTE is a big problem in cancer patients. According to most estimates, at least 1 in 5 cancer patients will develop a blood clot at some point in their natural history. Unfortunately, here, warfarin continues to be the dominantly used anticoagulant, even though for about 10 years, guidelines have been recommending low-molecular-weight heparin monotherapy for treatment. In terms of the newer agents, they have not been tested head-to-head versus warfarin, although they have been shown to have non-inferior efficacy compared to Coumadin, both in subgroup analyses of individual treatment trials as well as in pooled analyses of all of the NOAC cancer subgroups. There are also active cancer statistic studiesunderway with some of the newer oral agents. At this time, clinical guidelines are still recommending low-molecular-weight heparin therapy, although based on some data presented at ASH, it appears that the use of novel oral agents may be increasing in this population and certainly in settings where you re considering warfarin or in the setting of after 6 months of treatment where there are no data, it is not unreasonable to use NOACs in this setting. If you re just tuning in, you are listening to CME on ReachMD. I m your host, Dr. Jennifer Caudle, and today I m speaking with Dr. Alok Khorana. Dr. Khorana, what are some of the bleeding risks that are associated with novel oral anticoagulants and how do they compare to warfarin? 2017 ReachMD Page 5 of 9
6 Well, the major side effect of anticoagulation, any anticoagulation, is bleeding. There s been a lot of concern about bleeding as related to the newer oral agents, but it s important to understand that bleeding occurs in any patient on anticoagulation. It s sort of the predictable side effect of anticoagulation. There s one study from 2013 that shows that over a 12-month period there were about 6-1/2 million patients taking anticoagulants in the US of whom about 5% presented to the ER with a bleeding event and two-thirds of those patients needed to be hospitalized. So, bleeding is very common in this population unfortunately, just based on the mechanism of action which is to make the blood less coagulable. However, when you look at NOACs, there is a very nice Cochrane review that compared NOACs to conventional treatment for DVT, looking at 11 studies with over 25,000 participants, and the conclusion was efficacy is similar and the bleeding risk is lower with NOACs than with conventional treatment of VTE. So, one of the benefits of warfarin is that it can be reversed and currently there are no approved reversal agents for the novel oral anticoagulation agents, or NOACs. So, what is in the pipeline for novel oral anticoagulation reversal agents and how close are we really to seeing them used in practice? Yes, so this has been a big criticism of the novel oral agents, is that there s not an approved reversal agent, or there wasn t until very recently, and to some extent it s more of a concern in the case of rarebut-critical situations as there may be life-threatening bleeding. As I mentioned, bleeding generally is less relevantto warfarin and maybe a slightly lower rate compared to warfarin with the NOACs. But of course for clinicians it s important that even on the rare occasions when there is a life-threatening bleed happening that there will be a reversal agent that can safely bring the patient to a better situation. So, there have been ongoing studies with multiple reversal agents. One was actually just approved. This is a drug called idarucizumab, or Praxbind, which is approved specifically for patients on dabigatran. There are two other agents that are currently in clinical development, andexanet, which is an antidote for rivaroxaban, apixaban, and edoxaban that had a later-phase New England Journal paper earlier this year and is expected to get approval soon, and PER977 which is an antidote for all 4 novel oral agents. Each of these agents work differently in terms of their specificity, in terms of the mechanism, and the one that I mentioned, Praxbind, or idarucizumab, was just approved a few weeks ago and is already 2017 ReachMD Page 6 of 9
7 available on the market. Wonderful. How are the NOAC-related bleeding episodes currently managed? It s important to recognize most bleeding is not major bleeding. Number one, let s have patients just stop taking the drug and that should improve the situation very quickly in a very good situation. So there are also nonspecific reversal strategies that are available including the use of prothrombin complex concentrate, activated PCC, and recombinant factor VII, and all of these have shown some degree of efficacy. Dabigatran can at least be partially removed with hemodialysis, although the rationale for using that is less, now that we do have Praxbind available. And then oral charcoal may reduce dabigatran and apixaban absorption if it s not administered too late after the last drug intake. Well, let s examine a couple of specific cases and discuss treatment approaches. As we do this, let s discuss how to communicate with the patient to ease concerns and improve adherence to treatment. Case number one: Jason is a 70-year-old patient about to undergo total knee arthroplasty. He has type 2 diabetes and moderate impaired renal function. His GFR is 58 ml/min. Jason does not like needles and is concerned about bleeding risk. Can you discuss this case for us? Sure. So, this is an older patient who is about to undergo total knee replacement. He does have some comorbidities including diabetes and renal dysfunction and is not a fan of needles, as very few people are. In this setting, there are several agents that are available. I think it s well recognized with this setting, total knee replacement in the setting of comorbidities, does carry a high risk of venous thromboembolism, and is otherwise a very safe procedure. So it s important that we do what we can to prevent a VTE event from occurring. Agents that are available in this setting include low-molecular ReachMD Page 7 of 9
8 weight heparin, fondaparinux, apixaban, dabigatran, Coumadin, or aspirin. So for patients who are refusing injectable agents, as I mentioned, including the NOACs there s a bunch of oral anticoagulants available in this setting. It is important to make sure that patients understand the need for using a blood thinner in this setting and that they adhere to their oral agent if that is what you choose to use. Case number two: Maggie, is a 48-year-old breast cancer patient undergoing chemotherapy and she presents with complaints of right calf tenderness. Can you discuss this particular scenario? Cancer-related thrombosis is also a very common occurrence. It accounts for about 1 in 5 blood clots and 1 in 5 cancer patients get a blood clot. So, it s a fairly prevalent public health problem. As I mentioned, the guidelines recommend low-molecular-weight heparin monotherapy as being sort of the treatment of choice, but patients, especially in the United States, may refuse this, not just because of concerns about injectables, but also because of copayment issues related to injectables. So the appropriate guideline recommended treatment would be low-molecular-weight heparin monotherapy for up to 6 months. For patients who refuse that, using an oral anticoagulant in this setting would make sense. Options include warfarin, but this is a patient who is on chemotherapy, so you can certainly choose to use novel oral agents as they have less drug-drug interactions, known drug-drug interactions with chemotherapy. Certainly other decisions need to be made at the 6-month time point in patients in whom the cancer is in remission and who are not on active treatment. The general consensus is to discontinue anticoagulation at that time point, although there will still be a continued risk of recurrent VTE, but for the majority of patients who are going to continue to receive active treatment, the consensus is also to continue anticoagulation indefinitely, but there are no randomized data in the post- 6-month setting and so any of the oral anticoagulants, or continuing low-molecular-weight heparin would be an option at that time point. It is important to communicate to cancer patients that they remain at very high risk for recurrence, even on anticoagulation, but certainly if they go off of anticoagulation in the initial time period after diagnosis. So it s very important to make sure that patients understand why they re on a blood thinner and how important it is that they stay on it to prevent a fatalor significantly morbid complications, such as recurrent VTE, from happening ReachMD Page 8 of 9
9 Well, I d like to thank our guest, Dr. Khorana, for helping us better understand the role of NOACs in VTE treatment and prevention of recurrence. Thank you. Announcer Close This segment of CME on ReachMD is jointly provided by Global Education Group and Diversified Health Communications and supported by an educational grant from Boehringer Ingelheim. To receive your FREE CME credit or to download this segment, go to reachmd.com/cme. Thank you for listening ReachMD Page 9 of 9
Mabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationAnticoagulant Treatments for Special Patient Populations
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/anticoagulant-treatments-for-special-patientpopulations/3796/
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More information10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationA Case Review: Treatment-Naïve Patient with Advanced NSCLC: Smoker with Metastatic Squamous Cell Tumor
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationComplex Retrieval of Embedded Inferior Vena Cava Filters in Interventional Radiology
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/complex-retrievalembedded-inferior-vena-cava-filters-interventional-radiology/7838/
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationGlobal Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017
Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationUpdate on the Management of Cancer Associated VTE
Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationDisease Modifying Therapies in MS: Highlights from ACTRIMS 2018
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationTo prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban)
To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban) after hip or knee replacement surgery Always read the
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationDetect Cervical Cancer ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAbout Blood Clots and How to Treat Them
PATIENT & CAREGIVER EDUCATION About Blood Clots and How to Treat Them This information describes what a blood clot is and how it is treated. About Blood Clots When you have a cut or an injury, your blood
More informationUW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT
UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they
More informationWarfarin 2016: New State of the Art for an Old Drug
Warfarin 2016: New State of the Art for an Old Drug Dan Witt, PharmD Professor (Clinical) and Vice Chair, Department of Pharmacotherapy, Assistant Dean for Clinical Affairs, University of Utah College
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationThe era of NOACs. (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul
The era of NOACs (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul Head Pharmacist, Pitié Salpêtrière hospital Associate professor Paris Sorbonne University Disclosure Patrick
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationEffectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study Megan Roberts, PharmD, BCPS MUSC Medical Center and South Carolina
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationUnraveling Recent Cervical Cancer Screening Updates and the Impact on Your Practice
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationAnticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics
MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More information2019 ReachMD Page 1 of 5
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationVenous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Nursing A guide for patients and carers Contents Why do blood clots form in veins?... 1 How common is a deep vein thrombosis (DVT) or pulmonary embolus (PE)?... 2 How are DVTs/
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationDaiichi Sankyo s Once-Daily Lixiana
Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention
More informationPUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Cofact 250 IU and 500 IU powder and solvent for solution for injection PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cofact contains
More informationResults from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine
Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationRivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More information